CTAD 2024: Origin of lecanemab and real-world experience in its use
20 Jan 2025
byDr. Marwan Sabbagh, Barrow Neurological Institute, Phoenix, US; Dr. Lawrence Honig, Columbia University, New York City, US; Prof. Takeshi Iwatsubo, University of Tokyo, Tokyo, Japan; Prof. Lars Lannfelt, Uppsala University, Sweden
At the Clinical Trials on Alzheimer’s Disease (CTAD) 2024 Conference held in Madrid, Spain, researchers from the US and Japan shared real-world clinical experience with lecanemab, the first approved disease-modifying treatment for early Alzheimer’s disease (AD). Professor Lars Lannfelt of Uppsala University, Sweden, who received the CTAD Lifetime Achievement Award in recognition of his pioneering work that led to the development of the monoclonal antibody (mAb) drug, described the origins of his ground-breaking discovery.
